title: How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.
abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.|Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Fuji
authors.affiliation: Department of Hematology, University Hospital of Bern, Bern, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Rovó
authors.affiliation: Department of General Medicine, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohashi
authors.affiliation: Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Griffith
authors.affiliation: Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Einsele
authors.affiliation: Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kapp
authors.affiliation: Department of Haematology, Saint Antoine Hospital, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: N S
authors.initials: NS
authors.lastname: Majhail
authors.affiliation: Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
authors.forename: B G
authors.initials: BG
authors.lastname: Engelhardt
authors.affiliation: Department of Internal Medicine, Division of Hematology, University Hospital Basel, Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.affiliation: Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
authors.forename: B N
authors.initials: BN
authors.lastname: Savani
mesh_terms: D003920:Diabetes Mellitus / Q000209:etiology* / Q000628:therapy; D019468:Disease Management; D005544:Forecasting; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology* / Q000628:therapy; D014184:Transplantation, Homologous